Abstract: The present invention provides HIV aspartyl protease inhibitors of the formula; and when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein n is 3 or 4, wherein R1 may be, for example, iso-butyl, wherein X and Y, same or different, may be, for example, NH2 and F, and wherein R2 and R3 are as defined herein.

Abstract: An apparatus and method to auto-splice tapes in a tape dispensing machine where a continuous supply of tape is required. When a new roll of tape needs to be provided, a splicing apparatus or technique must permit to securely and efficiently make the connection between the first roll of tape and the new tape. The apparatus and method provide an open clip which engages one extremity of a running tape and one extremity of a stationary stand-by tape.

Abstract: A compound selected from the group consisting of a compound of formula I a compound of formula II and when the compound of formula I and II comprises an amino group pharmaceutically acceptable ammonium salts thereof, wherein R1, R2, Cx, n, R3, R4, R5, Y are as defined in the specification.

Abstract: A compound selected from the group consisting of a compound of formula I a compound of formula II and when the compound of formula I and II comprises an amino group pharmaceutically acceptable ammonium salts thereof, wherein R1, R2, Cx, n, R3, R4, R5, Y are as defined in the specification.

Abstract: A process for producing a thermoelectric material based on two or more elements selected in the group constituted by Bi, Sb, Te and Se, which process comprises: i. an alloying step wherein determined amounts of the elements Bi, Sb, Te or Se are mixed until an homogenous powdered alloy is obtained; ii. an extrusion step of the powdered homogenous alloy obtained in the preceding step. The elements Bi, Sb, Te or Se being preferably mechanically mixed in an homogenous powdered alloy. The thermoelectric material, which are obtainable by this process, exhibits improved thermoelectric and mechanical properties and are therefore suitable, for example, as cooler, as temperature stabilizer in a electronic device or as power generator.

Abstract: The present invention relates to support structures. The present invention in particular relates to a telescopic track as well as a telescopic mast assembly which may for example be exploited in the context of a person (e.g. patient) handling system.

Abstract: The endless track is made of a reinforced rubber material with longitudinally spaced and transversely disposed ridges or lugs. It is particularly well-adapted for recreational snowmobiles having a single track. The track is characterized in that the rubber material of the central portion of the body has a hardness of between 75 and 90 duro A while the rubber material of the opposite band portions of the body has a hardness between 55 and 75 duro A. Such track facilitates the steering capabilities of a snowmobile, particularly when the snowmobile is traveling on hard and abrasive surfaces. It also improves the durability of the track.

Abstract: The present invention provides HIV aspartyl protease inhibitors of the formula: and when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein n is 3 or 4, Y is O, S, NH or N—CN, wherein Cx may be, for example COOH, or CH2OH, wherein R1 is selected from the group consisting of a benzenesulfonyl group of formula II as defined herein, wherein R2 may be, for example, iso-butyl, or 3-methylbutyl, and wherein R3 and R4 are as defined herein.

Abstract: A compound of formula I′ and pharmaceutically acceptable derivatives thereof including, for example, where applicable or appropriate pharmaceutically acceptable salts thereof. Ar and Ar′ are aromatic or aryl type groups. The compounds have HIV integrase inhibitory properties. Ar, Ar′ and W may be as defined in the specification.

Abstract: A compound selected from the group consisting of a compound of formula I a compound of formula II and when the compound of formula I and II comprises an amino group pharmaceutically acceptable ammonium salts thereof, wherein R1, R2, Cx, n, R3, R4, R5, Y are as defined in the specification.

Abstract: The present invention relates to a class of amino acid derivatives with HIV aspartyl protease inhibitory properties.

Abstract: A beverage brewing apparatus having an automatic brew cycle mode and a semi-automatic brew cycle mode.

Abstract: A data processing system is provided for monitoring and recording the information flow and data, and making all calculations necessary for maintaining a Differential Continuous Compensation Plan (hereinafter referred to as “DCCP”) for participants to a Multi-Level Marketing approach (hereinafter referred to as “MLM”). MLM is defined as “an approach that remunerates participants for the purchases made by the people that they directly and indirectly introduced to particular products and/or services (hereinafter referred to as “offer”)”.

Abstract: An hydroxyphenyl derivative selected from the group consisting of a compound of formula and when a compound of formula I comprises a carboxylic acid group pharmaceutically acceptable salts thereof and when a compound of formula I comprises an amino group pharmaceutically acceptable ammonium salts thereof, wherein n is 1, 2 or 3, e is 1, 2 or 3, Hal represents a halogen atom (e.g. Cl, Br, F or I), p is 0, 1 or 2, r is 0, 1 or 2, X and X′ each independently represents a single bond, a saturated straight or branched hydrocarbon group of 1 to 4 carbon atoms or a straight or branched hydrocarbon group of 2 to 4 carbon atoms comprising a carbon to carbon double bond, Ra represents H or —CH3, and Raa represents H or —CH3; W may represent an amino acid residue or fragment. These compounds may be used to inhibit the activity of HIV integrase.

Abstract: The invention relates to a method of iteratively, selectively tuning the impedance of integrated semiconductor devices, by modifying the dopant profile of a region of low dopant concentration by controlled diffusion of dopants from one or more adjacent regions of higher dopant concentration through the melting action of a focussed heating source, for example a laser. In particular the method is directed to increasing the dopant concentration of the region of lower dopant concentration, but may also be adapted to decrease the dopant concentration of the region.

Abstract: A D-mannitol derivative selected from the group consisting of a compound of formula pharmaceutically acceptable derivatives thereof and where applicable or appropriate pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and R4 are the same or different and may each independently be selected from among alkyl and aryl (i.e. aromatic including aromatic like) groups. The D-mannitol derivatives may be used as HIV aspartyl protease inhibitors.